BiotechTube

barzolvolimab + Matching placebo

Phase 3Active
0 views this week 0 watching💤 Quiet
Interest: 38/100
38
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Chronic Spontaneous Urticaria

Conditions

Chronic Spontaneous Urticaria

Trial Timeline

Jul 11, 2024 → Apr 1, 2027

NCT ID
NCT06445023

About barzolvolimab + Matching placebo

barzolvolimab + Matching placebo is a phase 3 stage product being developed by Celldex Therapeutics for Chronic Spontaneous Urticaria. The current trial status is active. This product is registered under clinical trial identifier NCT06445023. Target conditions include Chronic Spontaneous Urticaria.

What happened to similar drugs?

20 of 20 similar drugs in Chronic Spontaneous Urticaria were approved

Approved (20) Terminated (3) Active (0)
✅Pegasys® + Pegasys®Chugai PharmaceuticalApproved
✅Telmisartan/Rosuvastatin 40/10mg + Telmisartan 40mgYuhanApproved
✅placebo + aspirin + clopidogrel + aspirin OR prasugrel + aspirinDaiichi SankyoApproved
✅alefacept + polyvalent pneumococcal vaccineAstellas PharmaApproved
✅alefaceptAstellas PharmaApproved
✅AlefaceptAstellas PharmaApproved
✅lysozyme 90 mg + PlaceboEisaiApproved

Hype Score Breakdown

Clinical
17
Activity
12
Company
9
Novelty
0
Community
0

Clinical Trials (7)

NCT IDPhaseStatus
NCT07266402Phase 3Recruiting
NCT06727552Phase 2Active
NCT06455202Phase 3Active
NCT06445023Phase 3Active
NCT05774184Phase 2Completed
NCT05405660Phase 2Completed
NCT05368285Phase 2Completed

Competing Products

20 competing products in Chronic Spontaneous Urticaria

See all competitors
ProductCompanyStageHype Score
Levofloxacin 500Dr. Reddy's LaboratoriesPre-clinical
23
mRNA-0184ModernaPhase 1
0
Lubiprostone + Lubiprostone + PlaceboDr. Reddy's LaboratoriesPhase 3
37
macitentan 10 mgBML, Inc.Phase 3
32
KPL-716 + PlaceboKiniksa PharmaceuticalsPhase 2
29
TERN-701Terns PharmaceuticalsPhase 1/2
36
Fludarabine + Cyclophosphamide + PRGN-3007PrecigenPhase 1
23
LY3556050 + PlaceboEli LillyPhase 2
35
THB001Third Harmonic BioPhase 1
11
BriquilimabJasper TherapeuticsPhase 1/2
26
BriquilimabJasper TherapeuticsPhase 1/2
14
BriquilimabJasper TherapeuticsPhase 2
29
Empagliflozin + Matching placeboEli LillyPhase 3
40
LY3461767 + PlaceboEli LillyPhase 1
29
Pirtobrutinib + Venetoclax + RituximabEli LillyPhase 3
44
LY3526318 + PlaceboEli LillyPhase 2
35
PirtobrutinibEli LillyPhase 2
42
Ibrutinib + LY3214996Eli LillyPhase 1
21
Pirtobrutinib + AcalabrutinibEli LillyPhase 2
27
LYR-210Lyra TherapeuticsPhase 2
25